TPIV Stock UPDATES Tapimmune Inc (TPIV) 0.9860 09/16/2014 15

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tapimmune Inc (TPIV) 0.9860 $TPIV

TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian and Breast Cancer
Business Wire - Tue Sep 16, 7:30AM CDT
TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of 5 naturally processed folate receptor alpha Class II antigenic epitopes. All five of the constituent peptides were found to be immunogenic and all patients developed immune responses to at least one and in most cases more than one of the vaccine peptides.

TapImmune, Inc. to Present at SeeThruEquity Microcap Conference
ACCESSWIRE - Thu Sep 04, 8:01AM CDT
Seattle, WA / ACCESSWIRE / September 4, 2014 / TapImmune, Inc. (OTCQB: TPIV), announces that company executives will attend and present at the SeeThruEquity Microcap Investor Conference to be held Thursday September 11th at the Convene Times Square, New York City. The presentation is scheduled for 10:00AM ET.

TapImmune Inc to Present at 16th Annual Rodman & Renshaw Healthcare Conference
ACCESSWIRE - Wed Sep 03, 9:42AM CDT
Seattle WA / ACCESSWIRE / September 3, 2014 / TapImmune, Inc. (OTCQB: TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease, will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The presentation will take place Wednesday, September 10th at 2:30 p.m. EDT in the Kennedy I Salon (4th floor) at the New York Palace Hotel in New York City.

SeeThruEquity Issues Update Note on TapImmune Highlighting New Grant Funded Clinical Trial and Recent Capital Raise of $2 Million
ACCESSWIRE - Tue Aug 19, 7:51AM CDT
New York, NY / ACCESSWIRE / August 19, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).

TapImmune, Inc. Announces $2 Million Registered Direct Offering
Business Wire - Mon Aug 11, 11:21AM CDT
TapImmune, Inc. (the "Company" , (OTCQB:TPIV), today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $2,000,000 of common stock at a price of $1.06 per share.

TapImmune's New Clinical Trial in Advanced Stage Ovarian Cancer Expands the Use of Folate Receptor Alpha Peptide Antigens
Business Wire - Thu Aug 07, 8:23AM CDT
TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial ovarian cancer has started at the Mayo Clinic, Rochester, MN. The folate receptor alpha peptides being used in this study are the same ones that are being used in a current Phase I study in breast and ovarian cancer. Folate receptor alpha is over a 100 fold elevated in 90% of ovarian cancer cells and is thus an excellent target for immunotherapy.

TapImmune Prevails in Legal Dispute with Michael Gardner
Business Wire - Thu Jul 24, 8:38AM CDT
TapImmune Inc. (OTCQB:TPIV), announces successful outcome of proceedings against Michael Gardner after almost 2 years of litigation.

New Immunotherapy Technologies Provide Hope In Breast and Ovarian Cancer
ACCESSWIRE - Wed Jul 23, 7:06AM CDT
Los Angeles / ACCESSWIRE / July 23, 2014 / Last month, TapImmune Inc. (OTCQB: TPIV) announced that Dr. Keith Knutson, PhD had been appointed to chair the company's scientific advisory board.

SeeThruEquity Issues Company Note on TapImmune Highlighting Valuation as Compared with Peers
ACCESSWIRE - Tue Jul 01, 8:02AM CDT
New York, NY / ACCESSWIRE / July 1, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company note on TapImmune Inc. (OTCQB: TPIV).

TapImmune elects Dr Keith Knutson as chair of its scientific advisory board
M2 - Fri Jun 13, 5:26AM CDT
Immunotherapy company TapImmune (Other OTC:TPIV) disclosed on Thursday the addition of Dr Keith Knutson, PhD as chair of its scientific advisory board.

TapImmune Appoints Leading Immunotherapy Researcher to Chair Scientific Advisory Board
Business Wire - Thu Jun 12, 4:16PM CDT
TapImmune Inc. (OTCQB:TPIV) is pleased to announce that Dr. Keith Knutson, PhD (www.vgtifl.org/keith-knutson-phd) has been appointed to chair the company's scientific advisory board. Dr. Knutson is Director of the Cancer Vaccines and Immune Therapies Program at the Vaccine & Gene Therapy Institute of Florida, a nonprofit biomedical research institute in Port St. Lucie, FL (VGTI Florida). TapImmune has licensed cancer vaccine technologies originating from Dr. Knutson's former laboratory at the Mayo Clinic, which are currently completing Phase I clinical trials in breast and ovarian cancer. The start of Phase II clinical studies in planned for the end of 2014. Glynn Wilson, TapImmune CEO said, "We are delighted to have someone with Keith's vision and scientific knowledge to lead our scientific advisory board. As a recognized leader in immunotherapy of breast and ovarian cancer, it is a great to have his input into the Company's clinical development programs. Under Dr. Knutson's leadership, TapImmune will continue to build a world-class scientific advisory board to review and advance all scientific programs."

TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress
ACCESSWIRE - Tue Feb 25, 8:42AM CST
SEATTLE, WA / Feb 25, 2014 / ACCESSWIRE / TapImmune Inc. (OTCQB:TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders.

Janssen Announces New Group Targeting Unmet Global Health Needs
PR Newswire - Wed Jan 22, 7:15AM CST
Janssen, the pharmaceutical companies of Johnson & Johnson, today announced the formation of Janssen Global Public Health (Janssen GPH), an important new group unifying Janssen's commitment to research, develop, and deliver transformational medicines to address the world's greatest unmet public health needs. Janssen GPH will align the company's groundbreaking science and innovative access models under a single entity to drive better health outcomes, improve quality of life for patients, and sustainably advance health for people all over the world.

TapImmune Chairman Provides Corporate Update on Development Programs & Collaborations
ACCESSWIRE - Wed Jun 26, 10:31AM CDT
Seattle, WA, June 26, 2013 (eTeligis via ACCESSWIRE) -- TapImmune (OTCQB: TPIV)

TapImmune Inc names Sherry Grisewood to board
M2 - Thu Mar 21, 9:37AM CDT
Vaccine company TapImmune Inc (OTC BB:TPIV) revealed on Wednesday the appointment of Sherry Grisewood, CFA to the board of directors.

TapImmune Announces the Appointment of Sherry Grisewood to the Board of Directors
PR Newswire - Wed Mar 20, 8:00AM CDT
TapImmune Inc. (OTCQB: TPIV) has pleasure in announcing the appointment of Sherry Grisewood, CFA to the Board of Directors. She has over 25 years securities industry experience in a range of investment banking, advisory and research-related activities. She currently has a senior banking and banking analytical role at Dawson James Securities. Prior to joining Dawson James, she was Managing Director, Lifesciences and Technology Banking for Tripoint Global Equities. Sherry served as Senior Life Sciences Banker at Jesup & Lamont Securities Corp. and as an independent strategic advisor and consultant for several investment banks over the prior 12 year period. She has participated in over 50 transaction-related projects worldwide involving initial public offerings, secondary offerings, PIPE's, private equity, M&A and licensing transactions in the life sciences sector. Prior to consulting for investment banks, Sherry served as Director of Research for several mid-tier brokerage companies and a leading independent

TapImmune Inc. to Present at the Florida Road Show Conference on March 14, 2013
PR Newswire - Wed Mar 13, 8:00AM CDT
TapImmune Inc. ("TapImmune" or the "Company" (OTCQB: TPIV), an immunotherapy company focused on the development of novel peptide and gene-based vaccine technologies, announced today that the Company will present at the Florida Road Show Conference in Boca Raton, Florida on Thursday, March 14, 2013. This conference, hosted by Corporate Roadshow and Undiscovered Equities, will feature presentations by CEOs and CFOs of promising emerging growth companies to an invited audience of investment bankers, analysts, hedge-fund managers, top brokers and accredited investors.

OTC Signal Daily Stock Watch
WorldStockWire - Tue Jan 22, 11:28PM CST
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com

Positive Interim Safety Analysis Achieved in Breast Cancer Patients Treated with HER2/neu Antigens
PR Newswire - Wed Jan 09, 8:00AM CST
TapImmune Inc. (OTCBB: TPIV) has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events. As a result treatment of the remaining 17 patients in the Phase I study, being conducted at Mayo Clinic, Rochester, MN will progress. The proprietary HER2/neu Class II antigens, discovered by Keith Knutson Ph.D. and colleagues at Mayo Clinic, show high affinity binding to human MHC proteins for ~84% of the population making it potentially applicable to a broad spectrum of HER2/neu patients compared to other approaches. The Phase I trial is being carried out in breast cancer patients who finished standard Herceptin®-based therapy and are at risk of disease recurrence. The primary endpoints of the study are safety and immunogenicity. Details of the Phase I trial can be found at http://clinicaltrials.gov. TapImmune is sponsoring the Phase I study and has an Exclusive Option to Li




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 343

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 34

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 306

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 0

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 635

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 110

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 119

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading

Top 5 Most Recently Viewed Articles

Cordance Medical Secures $8M Seed Funding for Brain Solutions

Updated Category News Views 235

Groundbreaking Seed Financing for Cordance Medical Cordance Medical, a leader in noninvasive focused ultrasound technology for treating brain diseases, has successfully completed an oversubscribed seed financing round. This milestone was highlighted by exceeding the initial $8 million target, with participation from both new and existing investors such as Shanda Grab...

Continue Reading
Man Group PLC Discloses Open Positions for Aviva PLC

Updated Category News Views 179

Man Group PLC Reports on Relevant Securities In a significant disclosure, Man Group PLC has announced its public opening position in relation to Aviva PLC, emphasizing transparency in its dealings concerning relevant securities. The regulations governing such disclosures necessitate comprehensive reporting, particularly when interests exceed 1% of the relevant securities....

Continue Reading
Baird Raises Griffon Corp Price Target to $92, Outperform Rating

Updated Category News Views 63

Baird Updates Griffon Corp's Stock Projection Baird has elevated its price target on shares of Griffon Corp (NYSE: GFF) from $84.00 to $92.00. This revision to the target price comes with a maintained Outperform rating, signaling strong confidence in the company's outlook. The analyst from Baird forecasts a gradual increase in Griffon's fiscal fourth-quarter financial...

Continue Reading
Experience SoCal Car Culture at SPARQ's LA Auto Show Exhibit

Updated Category News Views 316

SPARQ Returns to LA Auto Show with Exciting Exhibit California's automotive AI startup SPARQ is making waves by returning to the highly anticipated Los Angeles Auto Show this November. This year, visitors can expect an immersive experience inside the Concourse Hall, showcasing an impressive lineup of hypercars, Formula 1 vehicles, and famous cars from iconic films such as...

Continue Reading
Sagent Behavioral Health: A New Era for Mental Wellness Providers

Updated Category News Views 616

Sagent Behavioral Health: Transforming Behavioral Healthcare Sagent Behavioral Health marks a significant advancement in the provision of mental health services in the Midwest. With the consolidation of Nystrom & Associates and its affiliated brands, including Ellie Mental Health, LifeWorks, and several others, this new entity aims to create a unified and robust network...

Continue Reading